KPV Reconstitution Chart (Every Vial Size)

KPV Reconstitution Matrix & Quick-Reference Table

Reconstituting lyophilized peptides requires precise volumetric math to ensure reproducible concentrations across experimental assays. KPV (Lysine-Proline-Valine) is typically supplied as a lyophilized powder in standard laboratory vials ranging from 2 mg to 10 mg. When preparing stock solutions for in vitro cell culture or preclinical animal models, researchers must select appropriate volumes of sterile diluent to achieve target working concentrations.

The following matrix outlines resulting concentrations (mg/mL) and mass delivered per 0.1 mL (10 UI equivalent on standard laboratory micro-syringes) across common diluent volumes (1.0 mL, 2.0 mL, 2.5 mL, and 5.0 mL).

| Vial Mass | Diluent Volume | Final Concentration | Mass per 0.1 mL Aliquot | | :--- | :--- | :--- | :--- | | 2 mg | 1.0 mL | 2.0 mg/mL | 0.20 mg (200 µg) | | 2 mg | 2.0 mL | 1.0 mg/mL | 0.10 mg (100 µg) | | 2 mg | 2.5 mL | 0.8 mg/mL | 0.08 mg (80 µg) | | 2 mg | 5.0 mL | 0.4 mg/mL | 0.04 mg (40 µg) | | 5 mg | 1.0 mL | 5.0 mg/mL | 0.50 mg (500 µg) | | 5 mg | 2.0 mL | 2.5 mg/mL | 0.25 mg (250 µg) | | 5 mg | 2.5 mL | 2.0 mg/mL | 0.20 mg (200 µg) | | 5 mg | 5.0 mL | 1.0 mg/mL | 0.10 mg (100 µg) | | 10 mg | 1.0 mL | 10.0 mg/mL | 1.00 mg (1000 µg) | | 10 mg | 2.0 mL | 5.0 mg/mL | 0.50 mg (500 µg) | | 10 mg | 2.5 mL | 4.0 mg/mL | 0.40 mg (400 µg) | | 10 mg | 5.0 mL | 2.0 mg/mL | 0.20 mg (200 µg) |

For custom vial masses or non-standard reconstitutions, researchers can utilize our automated reconstitution calculator to determine exact volumetric values instantly.

Mathematical Formulas and Reconstitution Calculations

To calculate the concentration ($C$) of a reconstituted peptide solution, divide the total mass of the lyophilized peptide ($M$, in milligrams) by the total volume of diluent added ($V$, in milliliters):

$$C = \frac{M}{V}$$

To determine the specific mass ($m_{aliquot}$) delivered in a target sample volume ($V_{aliquot}$), multiply the concentration by the aliquot volume:

$$m_{aliquot} = C \times V_{aliquot}$$

Worked Example 1: A researcher reconstitutes a high-purity KPV 10mg vial using 2.0 mL of bacteriostatic water. Using the primary formula: $C = \frac{10\text{ mg}}{2.0\text{ mL}} = 5.0\text{ mg/mL}$. To determine the peptide mass delivered in a standard 0.1 mL volumetric draw: $m_{aliquot} = 5.0\text{ mg/mL} \times 0.1\text{ mL} = 0.5\text{ mg}$ (or 500 µg).

Worked Example 2: A laboratory protocol calls for a 5 mg vial to be reconstituted with 2.5 mL of sterile 0.9% sodium chloride. The concentration is calculated as $C = \frac{5\text{ mg}}{2.5\text{ mL}} = 2.0\text{ mg/mL}$. A 0.05 mL micropipette draw yields: $m_{aliquot} = 2.0\text{ mg/mL} \times 0.05\text{ mL} = 0.10\text{ mg}$ (or 100 µg).

Overview of KPV (Lysine-Proline-Valine) in Preclinical Research

KPV is a C-terminal tripeptide fragment (Lys-Pro-Val) derived from alpha-melanocyte-stimulating hormone (alpha-MSH). While parent alpha-MSH is a 13-amino-acid peptide that interacts with multiple melanocortin receptors (MC1R through MC5R), KPV retains significant biological activity while demonstrating distinct physicochemical and pharmacodynamic profiles in experimental models.

Preclinical literature demonstrates that KPV exerts potent anti-inflammatory effects without stimulating melanogenesis, making it a target of interest for isolating anti-inflammatory pathways from pigmentary signaling pathways. Research groups actively examine KPV across various all peptides offerings due to its short sequence length, high stability, and synthetic accessibility.

Because of its small molecular weight (341.42 g/mol), KPV exhibits rapid cellular uptake and favorable tissue distribution in preclinical assays. Research settings frequently investigate KPV in cellular models involving cytokine expression assays, epithelial barrier integrity studies, and experimental models of systemic or localized inflammation.

Biochemical Mechanism & Inflammatory Pathway Modulation

The primary mechanism of action attributed to KPV in preclinical research revolves around the inhibition of nuclear factor kappa B (NF-κB) nuclear translocation. NF-κB is a master transcription factor responsible for driving the expression of pro-inflammatory cytokines, including TNF-alpha, IL-1 beta, and IL-6.

In vitro data indicate that KPV enters target cells via PepT1 (peptide transporter 1), an influx transporter highly expressed in intestinal epithelial cells and immune populations. Once inside the cytoplasm, KPV interacts directly with signaling intermediates to suppress IκB phosphorylation, thereby preventing NF-κB subunits (p65 and p50) from entering the nucleus and initiating pro-inflammatory gene transcription.

Furthermore, animal models evaluating experimental colitis and intestinal barrier dysfunction demonstrate that KPV administration modulates tight junction protein expression (such as ZO-1 and Occludin). Preclinical studies suggest that by maintaining tight junction integrity and attenuating mucosal cytokine storms, KPV reduces epithelial permeability and preserves cellular architecture during challenge protocols.

Step-by-Step Reconstitution Protocol for Laboratory Settings

Aseptic technique must be strictly maintained throughout the reconstitution process to preserve product purity and prevent microbial contamination. Perform all procedures within a certified laminar flow hood or biosafety cabinet.

1. Preparation: Remove the KPV vial from cold storage (2–8°C or -20°C) and allow it to equilibrate to room temperature for 15–20 minutes to reduce condensation inside the vial prior to stopper penetration.

2. Sanitization: Swab the rubber septum of the peptide vial and the diluent vial with a fresh 70% isopropyl alcohol wipe. Allow them to air-dry completely.

3. Volumetric Withdrawal: Using a sterile, single-use syringe fitted with an appropriate gauge needle (e.g., 21G–25G), draw the precise volume of diluent indicated by your experimental protocol.

4. Gentle Addition: Direct the needle tip toward the inner glass wall of the KPV vial. Slowly inject the diluent so the liquid streams down the side rather than dropping directly onto the lyophilized cake, which can cause shearing or foaming.

5. Dissolution: Allow the diluent to fully saturate the cake. Gently swirl the vial in a circular motion. Never shake, vortex aggressively, or subject the solution to high shear stress, as this may destabilize the secondary structure.

6. Inspection: Visually inspect the solution. Reconstituted KPV should yield a clear, colorless, particulate-free liquid.

Diluent Selection & Solvent Compatibility

Choosing the appropriate diluent depends directly on the downstream experimental assay requirements, shelf-life demands, and cellular compatibility.

Bacteriostatic Water (0.9% Benzyl Alcohol): Standard diluent for multi-use research vials stored at refrigerated temperatures over extended periods (up to 28 days). The benzyl alcohol preservative prevents microbial proliferation.

Sterile 0.9% Sodium Chloride (Normal Saline): Preferred for in vivo animal models or physiological tonicity-sensitive cell cultures where benzyl alcohol may induce cellular toxicity or confound signaling pathways.

Phosphate-Buffered Saline (PBS, pH 7.4): Ideal for immediate in vitro cell culture assays requiring isotonic, pH-buffered conditions. Stock solutions prepared in unpreserved PBS should be used immediately or aliquoted and frozen to avoid bacterial contamination.

Dimethysulfoxide (DMSO): Generally unnecessary for KPV due to its high water solubility, but small percentages (<0.1% v/v final assay concentration) can be tolerated if co-solubilizing with hydrophobic compounds.

Comparative Analysis: KPV vs. Other Research Peptides in Barrier Models

When evaluating mucosal healing and barrier repair, researchers frequently compare KPV against other prominent compounds in our preclinical research hub. Three commonly evaluated peptides in intestinal and cutaneous models are BPC-157, LL-37, and Larazotide Acetate.

BPC-157 is a 15-amino-acid synthetic peptide known for promoting angiogenesis, extracellular matrix reorganization, and tissue repair via VEGFR2 activation. In contrast, KPV operates predominantly via PepT1-mediated NF-κB suppression, focusing directly on dampening acute inflammatory cascades rather than driving vascular proliferation.

LL-37 is an antimicrobial cathelicidin peptide that modulates immune responses and neutralizes lipopolysaccharides (LPS). While LL-37 offers direct antimicrobial activity, it can exhibit cytotoxicity at higher micromolar concentrations. KPV exhibits a favorable safety profile in cell culture, lacking direct cytotoxic properties while dampening LPS-induced cytokine release.

Larazotide Acetate acts primarily as a tight junction regulator through zonulin receptor antagonism. While Larazotide specifically targets tight junction disassembly, KPV provides a dual mechanism by preserving junctional proteins while simultaneously downregulating intracellular NF-κB signaling.

Analytical Quality, HPLC/MS Verification, and Endotoxin Standards

Experimental accuracy relies entirely on the purity and stability of reference compounds. Low-grade peptides containing truncated sequence impurities or high endotoxin levels introduce severe confounds into preclinical research, altering baseline cytokine release and cellular viability assays.

At PX1 Research, every batch of KPV is manufactured in USA-based, GMP-compliant facilities and undergoes rigorous analytical validation. Each lot is verified via High-Performance Liquid Chromatography (HPLC) to guarantee ≥98% chemical purity and Mass Spectrometry (MS) to confirm exact molecular weight.

Furthermore, our compounds undergo strict Limulus Amebocyte Lysate (LAL) testing to ensure endotoxin levels remain well below industry standard thresholds (<0.01 EU/µg). Researchers can review verified test data by requesting a lot-specific certificate of analysis prior to testing.

Laboratory Storage, Solution Stability, and Aliquoting Guidelines

Lyophilized KPV: Store dry lyophilized vials at -20°C for long-term storage (up to 24 months) or 2–8°C for short-term storage (up to 3 months). Protect vials from direct light exposure and moisture ingress.

Reconstituted Solutions: Once reconstituted with bacteriostatic water, KPV solution remains stable at 2–8°C for up to 28 days. Solutions reconstituted in unpreserved sterile water or PBS should be used within 24–48 hours if kept refrigerated.

Aliquoting & Freeze-Thaw Cycles: To prevent degradation over extended experimental timelines, reconstitute the stock solution, divide into single-use micro-aliquots using sterile polypropylene tubes, and immediately freeze at -20°C or -80°C. Avoid repeated freeze-thaw cycles, as physical ice crystal formation causes peptide degradation.

Institutions managing high-throughput research programs can register for a wholesale lab account to obtain bulk quantities with batch consistency across long-term studies.